# PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
Canonical URL: https://biopharmsignal.com/news/IMTX/prame-directed-cell-therapy-using-immatics-tcr-induces-deep-and-durable-remission-in-pediatric-patient-with-advanced-metastatic-nephroblastoma
Ticker: IMTX
Company: Immatics
Source: Immatics
Published: 2026-04-17 19:00 EST
Original Source URL: https://investors.immatics.com
## Summary

Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by Immatics  17-year-old adolescent with bulky, rapidly progressing nephroblastoma and no

## Article Body
Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by Immatics  17-year-old adolescent with bulky, rapidly progressing nephroblastoma and no
## Recent Company News
- 2026-06-01 12:00 EST — [Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/IMTX/immatics-presents-clinical-activity-and-response-dynamics-of-anzu-cel-prame-cell-therapy-at-2026-asco-annual-meeting) — Source: Immatics
- 2026-05-31 13:00 EST — [Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer](https://biopharmsignal.com/news/IMTX/immatics-presents-data-on-ima401-magea4-8-bispecific-at-2026-asco-annual-meeting-with-simultaneous-publication-in-nature-medicine-supporting-development-of-ima401-ima402-combination-in-lung-cancer) — Source: Immatics
- 2026-05-30 12:00 EST — [Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/IMTX/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-cancers-at-2026-asco-annual-meeting) — Source: Immatics
- 2026-05-12 11:00 EST — [Immatics Announces First Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/IMTX/immatics-announces-first-quarter-2026-financial-results-and-business-update) — Source: Immatics
- 2026-04-21 14:26 EST — [Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/IMTX/immatics-announces-four-upcoming-oral-presentations-across-its-clinical-cell-therapy-and-bispecific-portfolio-at-2026-asco-annual-meeting) — Source: Immatics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)